Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 742-756

  Kopylov, Uri ^a,b   Rosenfeld, Greg ^c   Bressler, Brian ^c   Seidman, Ernest ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

C reactive protein; Crohn's disease; Fecal biomarkers; Fecal calprotectin; Lactoferrin; Ulcerative colitis

Indexed keywords

CALGRANULIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MATRIX METALLOPROTEINASE; PROTEIN S 100; PYRUVATE KINASE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; S100A12 PROTEIN, HUMAN;

COLON RESECTION; DISEASE ACTIVITY; FECES ANALYSIS; HUMAN; ILEITIS; INFLAMMATORY BOWEL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REPRODUCIBILITY; REVIEW; TREATMENT RESPONSE; VIDEOENDOSCOPY; CHEMISTRY; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE COURSE; FECES; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; FECES; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MATRIX METALLOPROTEINASES; PREDICTIVE VALUE OF TESTS; PYRUVATE KINASE; RECURRENCE; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84898762070     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000442681.85545.31     Document Type: Review

References (103)

1. Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462-469.
2. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.e2.
3. Burri E, Beglinger C, Lehmann FS. Monitoring of therapy for inflammatory bowel disease. Digestion. 2012;86(suppl 1):1-5.
4. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
5. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275-1280.
6. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009;58:859-868.
7. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
8. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum. 2008;51:1283-1291.
9. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North America. 2012;41:483-495.
10. Dai J, Liu W-Z, Zhao Y-P, et al. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440-1444.
11. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
12. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
13. Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-1706.
14. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
15. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
16. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2- pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207-1212.
17. Fine KD, Ogunji F, George J, et al. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol. 1998;93:1300-1305.
18. Judd TA, Day AS, Lemberg DA, et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493-1499.
19. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706-1713.
20. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359-366.
21. Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374-1378.
22. Czub E, Herzig K-H, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147-1150.
23. Kolho KL, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43-50.
24. Annahazi A, Molnar T, Farkas K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis. 2013;19:316-320.
25. Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810-820.
26. Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-5589; discussion 8.
27. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur J Gastroenterol Hepatol. 2009;21:544-550.
28. Sipponen T, Haapamaki J, Savilahti E, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47:778-784.
29. Dabritz J, Langhorst J, Lugering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis. 2013;19:1130-1138.
30. Strid H, Simren M, Lasson A, et al. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis. 2013;7:e615-e622.
31. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
32. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-2837.
33. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455.
34. Canani RB, de Horatio LT, Terrin G, et al. Combined use of Noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9-15.
35. Schroeder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26:1035-1042.
36. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-39.
37. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009;44:446-456.
38. Ashorn S, Honkanen T, Kolho K-L, et al. Fecal calprotectin levels and Serological responses to Microbial Antigens among children and Adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15: 199-205.
39. Diamanti A, Panetta F, Basso MS, et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926-1930.
40. Van de Vijver E, Schreuder AB, Cnossen WR, et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child. 2012;97:1014-1018.
41. Wang S, Wang Z, Shi H, et al. Faecal calprotectin concentrations in gastrointestinal diseases. J Int Med Res. 2013;41:1357-1361.
42. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ (Clinical Research Ed). 2010;341:c3369.
43. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
44. Licata A, Randazzo C, Cappello M, et al. Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol. 2012;46:504-508.
45. Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012;49:44-54.
46. Poullis A, Foster R, Mendall MA. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573-574.
47. Wildt S, Nordgaard-Lassen I, Bendtsen F, et al. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19:567-574.
48. Yagmur E, Schnyder B, Scholten D, et al. Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Deutsche Medizinische Wochenschrift. 2006;131:1930-1934.
49. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol. 2013;48:1048-1054.
50. Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677.
51. Shastri YM, Bergis D, Povse N, et al. Prospective Multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med. 2008;121:1099-1106.
52. Balamtekin N, Baysoy G, Uslu N, et al. Fecal calprotectin concentration is increased in children with celiac disease: relation with histopathological findings. J Turkish Soc Gastroenterol. 2012;23:503-508.
53. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813.
54. Bremner A, Roked S, Robinson R, et al. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855-1858.
55. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as noninvasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-647.
56. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin Complements Routine laboratory Investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756-759.
57. af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528-537.
58. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45: 872-877.
59. Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol. 2010;45:325-331.
60. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther. 2004;20:615-621.
61. Zippi M, Al Ansari N, Siliquini F, et al. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease. La Clinica Terapeutica. 2010;161:e53-e56.
62. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694-700.
63. Koulaouzidis A, Rondonotti E, Karargyris A. Small-bowel capsule endoscopy: a ten-point contemporary review. World J Gastroenterol. 2013;19:3726-3746.
64. Kopylov U, Seidman EG. Clinical applications of small bowel capsule endoscopy. Clin Exp Gastroenterol. 2013;6:129-137.
65. Koulaouzidis A, Douglas S, RogersMA, et al. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol. 2011;46:561-566.
66. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis. 2010;16:1091-1092.
67. Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010; 31:323-330.
68. Kolho KL, Turner D, Veereman-Wauters G, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2012;55:436-439.
69. Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51:825-831.
70. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63:88-95.
71. Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37: 786-794.
72. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
73. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophilderived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091.
74. Meuwis MA, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis. 2013.
75. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
76. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858.
77. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
78. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti- TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14:1392-1398.
79. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104: 673-678.
80. De Vos M, Dewit O, D'Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562.
81. Vos MD, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117.
82. Panes J, Sandborn WJ, Zhang H, et al. Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. J Crohns Colitis. 2013; 7:S107S-S108S.
83. Berrill JW, Green JT, Hood K, et al. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51.
84. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrometype symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010; 105:1788-1794; quiz 95.
85. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103: 2007-2014.
86. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152.
87. Gisbert JP, Bermejo F, Perez-Calle J-L, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
88. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
89. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
90. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
91. Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:1143-1151.
92. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10:17-22.
93. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674.
94. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis. 2013.
95. Lobaton T, Rodriguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034-1042.
96. Scarpa M, D'Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum. 2007; 50:861-869.
97. Pakarinen MP, Koivusalo A, Natunen J, et al. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Inflamm Bowel Dis. 2010;16:482-486.
98. Thomas P, Rihani H, Roseth A, et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214-220.
99. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003;38:409-414.
100. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1280-1286.
101. Gonsalves S, Lim M, Finan P, et al. Fecal lactoferrin: a noninvasive fecal biomarker for the diagnosis and surveillance of pouchitis. Dis Colon Rectum. 2013;56:733-737.
102. Walkowiak J, Banasiewicz T, Krokowicz P, et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40:1493-1494.
103. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. [published online ahead of print August 1, 2013]. doi: 10.1016/j.cgh.2013. 07.022.